Synthesis and DNase I inhibitory properties of new benzocyclobutane-2,5-diones
Samo za registrovane korisnike
2019
Autori
Bondžić, BojanDžambaski, Zdravko
Kolarević, Ana
Đorđević, Aleksandra
Anderluh, Marko
Šmelcerović, Andrija
Članak u časopisu (Objavljena verzija)
,
Newlands Press
Metapodaci
Prikaz svih podataka o dokumentuApstrakt
Eight new benzocyclobutane-2,5-diones (1a–1h) were synthesized, and their inhibitory properties
against bovine pancreatic DNase I were examined in vitro. Methods & results: Compounds 1a–1h
were synthesized using photocycloaddition of duroquinone with various phenyl-substituted ethylenes
in the presence of 18W compact fluorescent lamp (visible light). Two compounds, 1,3,4,6-tetramethyl-7-
phenylbicyclo[4.2.0]oct-3-ene-2,5-dione (1a) and 1,3,4,6-tetramethyl-7-p-tolylbicyclo[4.2.0]oct-3-ene-2,5-
dione (1b) inhibited DNase I in a noncompetitive manner with IC50 values below 150 μM and showed to
be more potent DNase I inhibitors than crystal violet, used as a positive control. In order to analyze potential
binding sites for the studied compounds with DNase I, molecular docking study was performed.
Conclusion: The studied benzocyclobutane-2,5-diones offer a good starting point for a design of new
DNase I inhibitors.
Ključne reči:
benzocyclobutane-2,5-diones / DNase I inhibition / Lineweaver–Burk plot / molecular docking / synthesisIzvor:
Future Medicinal Chemistry, 2019, 11, 18, 2415-Izdavač:
- Future Medicine Ltd.
Finansiranje / projekti:
- Eksperimentalna i teorijska proučavanja reaktivnosti i biološka aktivnost stereodefinisanih tiazolidina i sintetičkih analoga (RS-172020)
- Dobijanje, fizičko-hemijska karakterizacija, analitika i biološka aktivnost farmakološki aktivnih supstanci (RS-172044)
- Faculty of Medicine of the University of Nis (internal project no. 4)
- Slovenian Research Agency (grant no. P1-0208)
DOI: 10.4155/fmc-2019-0032
ISSN: 1756-8919
PubMed: 31526044
WoS: 000498836900006
Scopus: 2-s2.0-85072993481
Institucija/grupa
IHTMTY - JOUR AU - Bondžić, Bojan AU - Džambaski, Zdravko AU - Kolarević, Ana AU - Đorđević, Aleksandra AU - Anderluh, Marko AU - Šmelcerović, Andrija PY - 2019 UR - https://cer.ihtm.bg.ac.rs/handle/123456789/3957 AB - Eight new benzocyclobutane-2,5-diones (1a–1h) were synthesized, and their inhibitory properties against bovine pancreatic DNase I were examined in vitro. Methods & results: Compounds 1a–1h were synthesized using photocycloaddition of duroquinone with various phenyl-substituted ethylenes in the presence of 18W compact fluorescent lamp (visible light). Two compounds, 1,3,4,6-tetramethyl-7- phenylbicyclo[4.2.0]oct-3-ene-2,5-dione (1a) and 1,3,4,6-tetramethyl-7-p-tolylbicyclo[4.2.0]oct-3-ene-2,5- dione (1b) inhibited DNase I in a noncompetitive manner with IC50 values below 150 μM and showed to be more potent DNase I inhibitors than crystal violet, used as a positive control. In order to analyze potential binding sites for the studied compounds with DNase I, molecular docking study was performed. Conclusion: The studied benzocyclobutane-2,5-diones offer a good starting point for a design of new DNase I inhibitors. PB - Future Medicine Ltd. T2 - Future Medicinal Chemistry T1 - Synthesis and DNase I inhibitory properties of new benzocyclobutane-2,5-diones VL - 11 VL - 2426 IS - 18 SP - 2415 DO - 10.4155/fmc-2019-0032 ER -
@article{ author = "Bondžić, Bojan and Džambaski, Zdravko and Kolarević, Ana and Đorđević, Aleksandra and Anderluh, Marko and Šmelcerović, Andrija", year = "2019", abstract = "Eight new benzocyclobutane-2,5-diones (1a–1h) were synthesized, and their inhibitory properties against bovine pancreatic DNase I were examined in vitro. Methods & results: Compounds 1a–1h were synthesized using photocycloaddition of duroquinone with various phenyl-substituted ethylenes in the presence of 18W compact fluorescent lamp (visible light). Two compounds, 1,3,4,6-tetramethyl-7- phenylbicyclo[4.2.0]oct-3-ene-2,5-dione (1a) and 1,3,4,6-tetramethyl-7-p-tolylbicyclo[4.2.0]oct-3-ene-2,5- dione (1b) inhibited DNase I in a noncompetitive manner with IC50 values below 150 μM and showed to be more potent DNase I inhibitors than crystal violet, used as a positive control. In order to analyze potential binding sites for the studied compounds with DNase I, molecular docking study was performed. Conclusion: The studied benzocyclobutane-2,5-diones offer a good starting point for a design of new DNase I inhibitors.", publisher = "Future Medicine Ltd.", journal = "Future Medicinal Chemistry", title = "Synthesis and DNase I inhibitory properties of new benzocyclobutane-2,5-diones", volume = "11, 2426", number = "18", pages = "2415", doi = "10.4155/fmc-2019-0032" }
Bondžić, B., Džambaski, Z., Kolarević, A., Đorđević, A., Anderluh, M.,& Šmelcerović, A.. (2019). Synthesis and DNase I inhibitory properties of new benzocyclobutane-2,5-diones. in Future Medicinal Chemistry Future Medicine Ltd.., 11(18), 2415. https://doi.org/10.4155/fmc-2019-0032
Bondžić B, Džambaski Z, Kolarević A, Đorđević A, Anderluh M, Šmelcerović A. Synthesis and DNase I inhibitory properties of new benzocyclobutane-2,5-diones. in Future Medicinal Chemistry. 2019;11(18):2415. doi:10.4155/fmc-2019-0032 .
Bondžić, Bojan, Džambaski, Zdravko, Kolarević, Ana, Đorđević, Aleksandra, Anderluh, Marko, Šmelcerović, Andrija, "Synthesis and DNase I inhibitory properties of new benzocyclobutane-2,5-diones" in Future Medicinal Chemistry, 11, no. 18 (2019):2415, https://doi.org/10.4155/fmc-2019-0032 . .